MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 199 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.76 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,649 | -49.5% | 518 | -20.2% | 0.01% | -42.1% |
| Q2 2023 | $149,919 | -62.0% | 649 | -60.2% | 0.02% | -64.8% |
| Q1 2023 | $394,642 | -29.5% | 1,629 | -15.6% | 0.05% | -32.5% |
| Q4 2022 | $559,892 | +347.9% | 1,929 | 0.0% | 0.08% | +281.0% |
| Q3 2022 | $125,000 | -26.5% | 1,929 | +10.5% | 0.02% | -27.6% |
| Q2 2022 | $170,000 | -9.6% | 1,746 | -8.9% | 0.03% | 0.0% |
| Q1 2022 | $188,000 | -6.0% | 1,917 | -18.7% | 0.03% | -3.3% |
| Q4 2021 | $200,000 | +46.0% | 2,358 | +37.2% | 0.03% | +30.4% |
| Q3 2021 | $137,000 | -19.4% | 1,719 | -1.5% | 0.02% | -20.7% |
| Q2 2021 | $170,000 | +7.6% | 1,746 | +29.1% | 0.03% | +3.6% |
| Q1 2021 | $158,000 | +113.5% | 1,352 | +102.7% | 0.03% | +100.0% |
| Q4 2020 | $74,000 | +42.3% | 667 | +53.3% | 0.01% | +27.3% |
| Q3 2020 | $52,000 | +100.0% | 435 | +90.0% | 0.01% | +83.3% |
| Q2 2020 | $26,000 | – | 229 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |